Psoriatic arthritis is a kind of arthritis that affects certain people who have psoriasis, a skin condition characterised by red areas of skin covered in silvery scales. Psoriasis usually develops years before psoriatic arthritis is diagnosed. However, for some people, joint issues arise earlier or at the same time as skin patches.
Market companies are concentrating their efforts on obtaining regulatory approvals for their drugs, which is projected to fuel the worldwide Psoriatic Arthritis Treatment Market growth throughout the forecast period. For example, Sandoz, a Novartis business, reported in October 2018 that the US Food and Drug Administration (FDA) had authorised its biosimilar, Hyrimoz (adalimumab-adaz). Rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in kids four years and older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulcerative colitis (UC), and plaque psoriasis were all approved by the US FDA (Ps).
During the projected period, prominent players' distribution agreements and collaborations are likely to enhance market growth. For example, Can-Fite BioPharma Ltd., a biotechnology company developing proprietary small molecule drugs for cancer, liver, and inflammatory diseases, announced in August 2019 that it had signed a distribution agreement with Kyongbo Pharm Co., Ltd., a pharmaceutical and medicine manufacturing company, to distribute Can-lead Fite's drug candidate, Piclidenoson (CF101), for the treatment of psoriasis in South Korea.
Read more @ https://cmiaspireblog.blogspot.com/2021/12/psoriatic-arthritis-treatment-market.html
